In summary, polymorphisms in the 5′-UTR of the TS gene and exon 6 (2522C/T) of the SLC19A1 gene appear to be potential prognostic factors for NSCLC patients treated with pemetrexed. The gene discussed is SLC19A1; the disease is non-small cell lung carcinoma.